Cite
Wang HL, Wei B, He HJ, et al. Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation . Theranostics. 2022;12(1):379-395doi: 10.7150/thno.67034.
Wang, H. L., Wei, B., He, H. J., Huang, X. R., Sheng, J. Y., Chen, X. C., Wang, L., Tan, R. Z., Li, J. C., Liu, J., Yang, S. J., Ma, R. C., & Lan, H. Y. (2022). Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation . Theranostics, 12(1), 379-395. https://doi.org/10.7150/thno.67034
Wang, Hong-Lian, et al. "Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation ." Theranostics vol. 12,1 (2022): 379-395. doi: https://doi.org/10.7150/thno.67034
Wang HL, Wei B, He HJ, Huang XR, Sheng JY, Chen XC, Wang L, Tan RZ, Li JC, Liu J, Yang SJ, Ma RC, Lan HY. Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation . Theranostics. 2022 Jan 01;12(1):379-395. doi: 10.7150/thno.67034. eCollection 2022. PMID: 34987651; PMCID: PMC8690916.
Copy
Download .nbib